Urologists' referral and radiation oncologists' treatment patterns regarding high‐risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis. Issue 1 (2nd December 2019)

• Record Type: Journal Article
• Authors: Egger, Sam; Smith, David P; Brown, Bernadette (Bea); Kneebone, Andrew B; Dominello, Amanda; Brooks, Andrew J; Young, Jane; Xhilaga, Miranda; Haines, Mary; O'Connell, Dianne L
• Is Part Of: Journal of medical imaging and radiation oncology. Volume 64:Issue 1(2020:Feb.)
• Page Start: 134
• Page End: 143
• Publication Date: 2019-12-02
• Subjects: adjuvant radiotherapy -- prostate cancer -- radiation oncologists -- referral -- urologists; Radiology, Medical -- Periodicals; Radiology, Medical -- Australasia -- Periodicals; 616.0757
• DOI: 10.1111/1754-9485.12979
• Languages: English
• ISSNs: 1754-9477

Abstract

Abstract: Introduction: Previous studies have observed low rates of adjuvant radiotherapy after radical prostatectomy (RP) for high‐risk prostate cancer patients. However, it is not clear the extent to which these low rates are driven by urologists' referral and radiation oncologists' treatment patterns. Method: The Clinician‐Led Improvement in Cancer Care (CLICC) implementation trial was conducted in nine public hospitals in New South Wales, Australia. Men who underwent RP for prostate cancer during 2013–2015 and had at least one high‐risk pathological feature of extracapsular extension, seminal vesicle invasion and/or positive surgical margins were included in these analyses. Outcomes were as follows: (i) referral to a radiation oncologist within 4 months after RP ('referred'); (ii) commencement of radiotherapy within 6 months after RP among those who consulted a radiation oncologist ('radiotherapy after consultation'). Results: Three hundred and twenty‐five (30%) of 1071 patients were 'referred', and 74 (61%) of 121 patients received 'radiotherapy after consultation'. Overall, the probability of receiving radiotherapy within 6 months after RP was 15%. The probability of being 'referred' increased according to higher 5‐year risk of cancer‐recurrence ( P < 0.001). Conclusion: Only 30% of patients with high‐risk features are referred to a radiation oncologist with the likelihood of referral being influenced by the perceived risk of cancer‐recurrence as well as the urologist's institutional/personal preference. When patients are seen by a radiation oncologist, 61% receive radiotherapy within 6 months after RP with the likelihood of receiving radiotherapy not being heavily influenced by increasing risk of recurrence. This suggests many suitable patients would receive radiotherapy if referred and seen by a radiation oncologist.